

ACL Laboratories COVID-19 and Influenza Activity Report


Updated: Oct 31, 2021



RESPIRATORY PATHOGEN PANEL Oct 31, 2021 Positivity Rate (%)



MONTH	FLU A Total	FLU A (H1N1)	2009 (H1N1)	FLU A (H3N2)	FLU B	RSV A	RSV B	RSV Total	PARA 1	PARA 2	PARA 3	PARA 4	Corona 229E	Corona NL63	Corona OC43	Corona HKU1	Meta pneumo	Entero Rhino	ADENO	BOCA	Legio nella	Chla mydia	Mycoplasma	
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0	
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0	
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1	
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0	
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1	
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1	
JUL	0.0	0.0	0.0	0.0	0.0	1.0	7.2	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	0.4	0.0	0.0	
AUG	0.0	0.0	0.0	0.0	0.0	0.8	12.5	13.3	0.0	1.2	6.2	0.1	0.1	0.1	0.5	0.0	0.7	14.0	1.3	3.6	0.0	0.0	0.0	
SEP	0.0	0.0	0.0	0.0	0.0	0.7	10.6	11.3	0.0	0.9	1.8	0.4	0.0	0.0	0.4	0.0	0.6	23.6	0.8	4.1	0.1	0.0	0.1	
OCT	0.0	0.0	0.0	0.0	0.0	0.5	7.3	7.8	0.0	1.6	1.2	1.0	0.1	0.0	0.4	0.0	0.3	21.0	1.2	4.0	0.2	0.0	0.0	
NOV																								
DEC																								

Increased prevalence of viruses: **Rhinovirus, RSV and Boca virus**



ACL RSV PCR and EIA positivity rates - trend down


CDC Data RSV pos rate for Region 5 Chicago - (PCR - **17%**↓, Antigen - **23%** ↓)




SARS-COV-2					Influenza - no activity				RSV (Antigen+PCR)			
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG	IL % RSVPCR	WI % RSVPCR
Oct 31	3.8	6.3	4.8	13.7	0.3	0	n/a	0	18.5	25.0	20.9	32.2
Oct 24	3.7	5.6	5.1	16.7	0	0.2	n/a	0	19.0	29.3	22.5	30.6
Oct 17	3.7	6.5	7.0	18.0	0	0	0	0	20.0	36.0	27.0	31.3
Oct 10	4.3	7.6	5.0	18.2	0	0.2	0	0	22.2	31.8	23.9	32.6
Oct 3	5.0	8.6	6.0	16.6	0	0	0	0	20.0	34.0	24.9	35.5
Sep 26	5.0	8.1	4.4	15.2	0	0	0	0	27.7	35.9	30.0	37.7
Sep 18	4.9	9.0	7.2	17.5	0	0	0	0	33.0	31.0	28.0	39.6
Sep 12	6.5	9.6	5.9	20.5	0	0	0	0	20.0	21.9	41.6	43.7
Sep 5	6.2	8.3	7.0	22.4	0	0	0	0	33.3	43.9	38.1	40.5
Aug 29	7.5	8.5	9.0	21.3	0	0	0	0	38.9	32.5	43.9	38.8
Aug 22	6.0	7.3	13.5	16.1	0	0	0	0	31.3	27.1	32.5	20.6

ACL RSV tests results are consistent with “atypical” RSV outbreak


ACL COVAG and SCVPCR - Pos rate (%) - Oct 31, 2021



Oct 27, 2021 - daily COVID-19 cases in US - CDC





Oct 23, 2021 – SARS-CoV-2 circulating in the US (~99.6% % Delta variants)




US vaccination status CDC | Data as of: Oct 28, 2021

417,795,537 Vaccines Administered	
221,348,530 People who received at least one dose	191,242,432 People who are fully vaccinated*
66.7% Percentage of the US population that has received at least one dose	57.6% Percentage of the US population that has been fully vaccinated*


ACL FLUPCR - Pos rate (%) - Oct 31, 2021



Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, May 23, 2021 – October 23, 2021





CDC Midwest data as of: Oct 23, 2021




2021-22 Influenza Season Week 42 ending Oct 23, 2021

ILI Activity Level




CSF targets positivity rate is 3.1%

ACL RMEPNL - CSF POSITIVE TARGETS - Oct 31, 2021



The most prevalent GI bacterial target is - (Campy and Giardia)



The most prevalent GI viral target is – (Adeno – 0.6%)

ACL GPP - STOOL POSITIVE VIRAL TARGETS - Oct 31, 2021

